JB

Jane Bell

Mesoblast Limited | Non-Executive Director
Ms. Bell AM has 30 years' experience as a banking and finance lawyer with leading law firms, financial services and corporate treasury operations in the United States, Canada, Australia and the United Kingdom. She is a Chair and non-executive Director in regulated sectors including delivery of healthcare, life sciences, medical research, and funds management. She currently serves as Deputy Chair of Monash Health; she is also a director of publicly listed biotechnology company Amplia Therapeutics.

Companies and Roles

Company
Title
Tenure
Since
MSB
MSB
Mesoblast Limited
  • Non-Executive Director
3yrs, 10mthAug 2022
ATX
ATX
Amplia Therapeutics Limited
  • Non-Executive Director
  • Non-Executive Chairman
5yrs, 3mthApr 2021

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ATX
ATX
Amplia Therapeutics Limited
30/03/26485,0363,176,715762,329N/A
MSB
MSB
Mesoblast Limited
30/06/25N/A622,492192,308N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ATX
ATX
Amplia Therapeutics Limited
01/09/25
Issued
240,590$0.165$39,697Issue of options
ATX
ATX
Amplia Therapeutics Limited
01/09/25
Issued
130,435$0.230$30,000Placement
MSB
MSB
Mesoblast Limited
28/02/25
Buy
79,051$2.530$199,999On-market trade
MSB
MSB
Mesoblast Limited
09/01/25
Issued
192,308$2.810$540,385Issue of options
ATX
ATX
Amplia Therapeutics Limited
20/12/24
Issued
521,739$0.083$43,304As advised by the company